Anja Krammer is the Chief Executive Officer of Turn Biotechnologies, a pre-clinical company with proprietary mRNA technology focused on fighting the effects of ageing. She has previously held senior and executive-level positions in several technology and healthcare companies, she has co-founded three Silicon Valley startups and she also has public company audit committee experience. Ms. Krammer received her Bachelor’s degree from the University of South Carolina and a certificate of International Trade from the University of Paris, Sorbonne.
